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B a c k g r o u n d / A i m s :  L i t t l e  i s  k n o w n  a b o u t  t h e  m a n a g e m e n t  o f  
o c c l u d e d  m u l t i p l e  m e t a l l i c  s t e n t  ( M S )  d e p l o y e d  i n  m a l i g n a n t  
h i l a r  b i l i a r y  s t r i c t u r e s  ( H B S ) .  T h e  p u r p o s e  o f  t h i s  s t u d y  w a s  t o  
e v a l u a t e  t h e  e n d o s c o p i c  m a n a g e m e n t  o f  o c c l u d e d  m u l t i p l e  M S s  
d e p l o y e d  i n  H B S .  M e t h o d o l o g y :  5 5  p a t i e n t s  w i t h  u n r e s e c t a b l e  
b i l i a r y  t r a c t  c a r c i n o m a  h a d  m u l t i p l e  M S s  i n s e r t e d  d u e  t o  H B S .  
T h e  e n d o s c o p i c  i n t e r v e n t i o n  t h r o u g h  t h e  d u o d e n a l  p a p i l l a  w a s  
p e r f o r m e d  o n  3 0  c a s e s  w h o  h a d  M S  o c c l u s i o n .  T h e  p r o c e d u r e  
s u c c e s s  r a t e ,  t h e  s u r v i v a l  t i m e  a f t e r  t h e  p r o c e d u r e ,  a n d  t h e  
n u m b e r  o f  e n d o s c o p i c  i n t e r v e n t i o n s  b e f o r e  d e a t h  w e r e  a n a l y z e d ,  
r e t r o s p e c t i v e l y.  R e s u l t s :  T h e  c a u s e s  o f  M S  o b s t r u c t i o n  w e r e  
t i s s u e  i n g r o w t h  ( n = 2 0 ) ,  s l u d g e  ( n = 7 ) ,  t u m o r  o v e r g r o w t h  ( n = 2 ) ,  
a n d  h e m o b i l i a  ( n = 1 ) .  E n d o s c o p i c  c l e a n i n g  o r  d e p l o y m e n t  o f  
p l a s t i c  s t e n t s  o r  M S s  w a s  p e r f o r m e d  o n  t h e s e  p a t i e n t s  a n d  w a s  
s u c c e s s f u l l y  a c c o m p l i s h e d  o n l y  v i a  t h e  t r a n s p a p i l l a r y  a p p r o a c h .  
T h e  s u r v i v a l  t i m e  a f t e r  M S  o b s t r u c t i o n  w a s  2 1 9  d a y s .  T h e  
m e d i a n  n u m b e r  o f  e n d o s c o p i c  i n t e r v e n t i o n s  b e f o r e  d e a t h  w a s  3 .  
T h e  m e d i a n  i n t e r v a l  o f  e n d o s c o p i c  i n t e r v e n t i o n  a f t e r  t h e  f i r s t  
p l a s t i c  s t e n t  o c c l u s i o n  w a s  8 4  d a y s .  C o n c l u s i o n s :  O u r  l o n g -
t e r m  d a t a  r e g a r d i n g  t h e  e n d o s c o p i c  m a n a g e m e n t  o f  o c c l u d e d  
M S s  d e p l o y e d  i n  m a l i g n a n t  h i l a r  b i l i a r y  s t r i c t u r e s  a r e  
a c c e p t a b l e  a l t h o u g h  t h e  p a t e n c y  t i m e  o f  p l a s t i c  s t e n t s  d e p l o y e d  
a f t e r  M S  o c c l u s i o n  w a s  r e l a t i v e l y  s h o r t .  
K E Y  W O R D S :  M a l i g n a n t  h i l a r  b i l i a r y  s t r i c t u r e ;  M e t a l l i c  s t e n t ;  
O b s t r u c t i o n ;  M a n a g e m e n t  
A B B R E V I AT I O N :  M e t a l l i c  s t e n t s  ( M S s ) ;  P l a s t i c  s t e n t s  ( P S s ) ;  
H i l a r  b i l i a r y  s t r i c t u r e s  ( H B S )  B i l i a r y  t r a c t  c a r c i n o m a  ( B T C )   
Abstract
INTRODUCTION  
Since metallic stents (MSs) provide relatively longer patency time than 
plastic stents (PSs), they have been widely applied to patients with 
malignant biliary strictures who are not amenable to surgical treatment  (1-
6). Although the endoscopic deployment of multiple MSs in malignant hilar 
biliary strictures (HBS) is technically demanding, recent several articles 
have reported its satisfactory outcomes (7-13). Apart from the challenges 
involved in their deployment, the subsequent occlusion of MSs is not rare 
(3%–39.1%) (8), and its management depends on the case  (10). Generally, 
percutaneous or transpapillary biliary decompression is chosen to 
ameliorate the morbidities associated with MS occlusion. To provide good 
outcomes to these patients, the management of occluded MSs is one of the 
greatest concerns, because insufficient decompression induces  a worse 
prognosis (14). Due to the complicated structures at the confluence 
constructed with the MS deployed with a partial stent -in-stent procedure, 
the management of occluded MS would appear to be difficult  (11). 
However, we demonstrated in our previous report that the management of 
occluded MS was feasible and safe  (7), and the negotiation of interstices 
with hydrophilic guidewire was not as difficult as expected. We usually 
insert two or more PSs through the MS interstices at the confluence and 
place the distal end in the intrahepatic ducts. The merit of PSs is that they 
are exchangeable in the case of PS occlusion. However, the long-term 
outcomes of this procedure are limited. Furthermore, treatment other than 
endoscopic PS deployment may be necessary sometimes. In this study, we 
analyzed our transpapillary management of occluded MS deployed in HBS 
caused by unresectable biliary tract carcinoma (BTC) and evaluated the 
merits and drawbacks of this treatment for these patients.  
METHODOLOGY  
Patients  
Between January 2004 and March 2009, we inserted multiple MSs in 55 
consecutive patients with unresectable cholangiocarcinoma or gallbladder 
Manuscript
carcinoma. The patient demographic data are shown in the left column of 
Table 1. The diagnosis was made principally via imaging modalities. 
Histological or cytological confirmation of malignancy was obtain ed from 
all patients. Each patient had 2 or more JOSTENT SelfX units deployed via 
the endoscopic retrograde route using a partial stent -in-stent procedure. 
The technique of multiple MS deployment using a partial stent -in-stent 
procedure has been described elsewhere (7-13). The number of branches 
achieved after MS deployment depended on the case, but we made 2 or 3 or 
4 branches using this technique. Written informed consent was obtained 
from all patients, and our ethical committee approved the protocol. Aft er 
successful MS deployment, 42 patients received chemotherapy with either 
gemcitabine (n=34; 600 –1000 mg/m2/wk, weekly for 3 of every 4 weeks) 
or S-1 (an oral fluorouracil antitumor drug that combines 3 pharmacologic 
agents: tegafur, which is a prodrug of 5-fluorouracil; 5-chloro-2,4-
dihydroxypyridine,which inhibits dihydropyrimidine dehydrogenase 
activity; and potassium oxonate, which reduces gastrointestinal toxicity; 
n=8; 80 mg/body/day, for 2 of every 3 weeks).  
Stent occlusion  
These patients were observed until August 2010. During this period, 50 
patients (90.9 %) died and 30 patients (54.5 %) experienced MS occlusion. 
These patients’ demographic data are shown in the right column of Table 1. 
Stent occlusion was suspected in patients with laboratory parameters that 
indicated cholestasis, fever, and/or jaundice. The cause of stent occlusion 
was confirmed with endoscopic examination with IDUS. Usually, the 
occluded region in the MS lumen showed up as a radiopaque thread or 
defect with contrast material, where an echogenic soft -tissue density was 
observed with IDUS. We defined the cause as tissue ingrowth, when the 
occluded region remained in the same condition as the contrast materials 
after intraductal movement of the retrieval balloon. On the other hand, 
when it disappeared after this procedure, the cause was conceived as debris 
or sludge. In this case, debris or sludge appeared from the duodenal papilla. 
Occasionally, the edge of the occlusion exceeded one or both ends of the 
MS even after the previous motion of the retrieval balloon. In this case, the 
cause was defined as tissue overgrowth whether the tissue ingrowth was 
accompanied or not. In addition, most cases with tissue ingrowth or 
overgrowth accompanied the sludge in the stent lumen. In this study, when 
the cause of MS occlusion was defined as sludge, the patients had neither 
tissue ingrowth nor tissue overgrowth.   
Endoscopic intervention to occluded MS 
For the treatment of a patient with suspected MS occlusion, transpapillary 
biliary decompression was chosen as an initial therapy. We usually inserted 
multiple 7-Fr plastic stents (Zimmon-type plastic stent; Wilson-Cook 
Medical Inc.) into 2, 3 or 4 lobes through the lumen of the previously 
deployed MS, because the confluence of mult iple MSs was involved in all 
cases. The technique for the deployment of multiple plastic stents through 
the lumen of an occluded MS is as follows (Figure 1)  (15). After the 
repetition of deep cannulation into the common bile duct, 2 guidewires 
were inserted into the target hepatic ducts. To negotiate the stricture and 
MS interstices, it is very important to choose an appropriate guidewire. 
Usually, we employed Revowave (Piolax Medical Devices, Yokohama, 
Japan), or Radifocus (Terumo, Tokyo, Japan). These guidewires have a 
flexible and hydrophilic tip with deep angle and excellent torque -
conductivity. After the tip of the guidewire reached the target hepatic duct, 
the guidewire was exchanged for a 0.035-inch THSF (Wilson-Cook Medical 
Inc, Winston-Salem, NC) with the over-the-wire technique, because we 
needed stiffness to allow the tip of a plastic stent to pass through the 
stricture and interstices. In addition, when three plastic stents were 
inserted into the occluded three-branched MS, three THSFs were not pl aced 
at the same time, simply because three THSFs interfere with the movement 
of the scope and its elevator due to their excessive stiffness. Therefore, we 
recommend two-guidewire placement at one time. The third guidewire 
should be inserted into the remaining branch after the deployment of the 
first plastic stent. When the cause of MS occlusion was sludge, we 
removed the sludge with a retrieval balloon catheter (Multi -3V Extraction 
Balloon, proximal injection type; Olympus). The sludge was removed via 
the pull-motion of the inflated balloon catheter or washed out via saline 
injection (Figure 2). When the cause was tumor overgrowth to the 
papillary end, an additional MS was inserted to the papillary end. In one 
case, the MS edge at the papillary end made the  common bile duct kinked, 
and sludge was formed in the MS lumen. To accommodate the axis of the 
MS to the common bile duct, we deployed another MS in the common bile 
duct with its distal end exposed in the duodenum (Figure 3). When the 
obstruction was at the intrahepatic end, multiple PSs were deployed.  
We evaluated the technical success and clinical success of our procedures. 
Technical success was defined as the successful deployment of plastic or 
metallic stents or the opacification of the stent lumen aft er the removal of 
sludge. Clinical success implies the discharge of the patient with clinical 
improvement after the procedures.  
Statistical analysis 
Statistical analyses of patient data and clinical parameters are shown in 
terms of median and range. Overall survival time and MS patency time of 
all patients and patients with MS occlusion, patient’s survival after MS 
obstruction, and PS patency time were analyzed by the Kaplan -Meier 
method. Survival was defined as the time from MS obstruction to death o r 
the date of last follow-up evaluation. Patency time was defined as the time 
from the stent deployment to the endoscopic intervention for the treatment 
of stent occlusion. All analyses were performed with Statistical Analysis 
System software, version 8 (SAS Institute, Inc., Cary, NC).  
RESULTS  
The mean patency time of occluded MS was 139 days (range, 21 -1590 
days). Major findings of MS occlusion were increase of liver and biliary 
tract enzymes (n=30: 100%), fever (n=24: 79%), and bile duct dilation on 
medical imaging (n=22: 75%). The causes of MS occlusion and its relation 
with the endoscopic treatment are shown in Table 2. Tissue ingrowth was 
the main cause of MS occlusion (n=20: 66.7%). To treat the morbidities 
associated with MS occlusion, stent deployment was the major procedure 
(83.3%: 25/30). We deployed PS in 21 cases (70%) and MS in 4 cases 
(13.3%). Multiple PS deployment was performed in 20 patients, whose 
cause of MS occlusion was tissue ingrowth involving the confluence 
(n=19) and hemobilia (n=1). One patient had MS occlusion at the 
confluence. However, due to severe right hepatic atrophy with tumor 
involvement, one PS was adequate to resolve the jaundice. In three patients, 
a kink of the common bile duct at the papillary end of the MS caused 
sludge. Therefore, we corrected the form of the common bile duct with a 
PS (n=1) or MS (n=2) after the removal of sludge. In the latter cases, the 
distal end of the MS was placed in the duodenal lumen. In the remaining 2 
cases with additional MS deployed, tissue  ingrowth or overgrowth existed 
in the common bile duct. These procedures were successfully accomplished 
only via the transpapillary route. All patients became outpatients after 
these technically successful procedures addressing the first event of MS 
obstruction. The overall survival time after MS obstruction was 219 days  
(Figure 4) . The median number of endoscopic interventions during their 
survival was 3 (range 1–16; one time, n=6; two to three times, n=14; four 
or more, n=10). The median interval of the endoscopic intervention after 
the first PS occlusion was 84 days and its patency curve is shown in Figure 
5. The correlation between the number of PS exchanges and the median 
interval of the PS exchange is shown in Table 3. As the number of PS 
exchanges increased, the interval tended to become shorter, but the 
difference was not significant (p=0.053).  
DISCUSSION 
Recent development of effective antitumor drugs, such as gemcitabine, and 
their combination therapy has contributed to longer survival of patients 
with BTC (16,17). Therefore, the management of HBS has become more 
important than ever before for patients with BTC, because inadequate 
biliary decompression jeopardizes their lives despite the anticipated longer 
life expectancy. For more than 6 years, we have deployed multiple MSs in 
cases with unresectable HBS caused by BTC, due to the long patency and 
acceptable complications of this therapy. Furthermore, we have 
demonstrated that multiple MS deployment is applicable even to patients 
who were receiving chemotherapy for this morbidity (7). Recently, several 
studies regarding the endoscopic management of HBS with deployment of 
multiple MSs have been conducted (10-13). Some of the studies have 
mentioned the technical feasibility of the endoscopic procedure a fter MS 
occlusion. However, the outcomes of patients with MS occlusion have not 
been sufficiently evaluated in the literature. In this retrospective study, we 
analyzed the outcomes of patients with MS occlusion and demonstrated 
that endoscopic management of the occluded multiple MSs achieved 
satisfactory technical and clinical outcomes. Furthermore, even after MS 
occlusion, a long survival was attained with this procedure although 
frequent endoscopic intervention was mandatory after MS occlusion due to 
the short patency of the plastic stents deployed.  
Several conditions such as tumor invasion to MS, tissue hyperplasia, and 
sludge jeopardize the MS patency (18). When MS occlusion is suspected in 
patients with fair condition, we should conduct an appropriate t reatment 
for them to live as long as possible. We usually perform an interventional 
endoscopic procedure on these patients via the transpapillary route. In this 
study, tissue ingrowth was the main cause of MS occlusion. Under such 
conditions, we employed multiple PSs because the site of MS occlusion 
usually includes the hilar portion. To avoid cholangitis in the undrained 
segment, we deployed as many PSs as possible. Furthermore, we could 
repeat this procedure in the case of PS occlusion, because the exchan ge of 
the occluded PS was feasible under the endoscopic procedure. It is true that 
this procedure is somewhat technically demanding, especially in 
negotiating the interstice at the hilar portion with guidewire and in making 
the tip of the PS pass through i t afterward. However, recent advancements 
in devices and instruments have enabled us to overcome these technical 
difficulties. Incidentally, the proximal end of MS deployed in the 
intrahepatic duct became a guide to advancing the tip of the guidewire. 
Therefore, if only the MS is placed in the appropriate direction, we can 
provide favorable management of a patient with HBS even under MS 
occlusion. Furthermore, although the patency time of PSs deployed under 
MS occlusion was not particularly satisfactory, we  would like to emphasize 
that all patients became outpatients without external catheterization after 
the first endoscopic procedure. It has been suggested that multiple PS 
deployment after MS occlusion is one of the choices for salvaging patients 
with HBS due to unresectable BTC. Park et al have reported a biliary 
diversion technique using EUS-guided hepaticogastrostomy for an occluded 
biliary metal stent after failed ERCP (19). We think this could become 
another salvage procedure if we fail  in the transpapillary approach.  
We must admit that there are several limitations to this study: it was 
retrospective in nature, with a small sample size and conducted in a single 
center. However, the number of patients with HBS due to BTC is generally 
small and the follow-up of patients after MS deployment can be difficult, 
because of the typically advanced age of the patient. Nevertheless, this 
study was conducted under uniform conditions regarding the type of MS 
deployed. Furthermore, the number of patients who were followed-up is 
acceptable. Therefore, our results may become a reference to compare the 
outcomes of management for patients with HBS due to BTC. However, the 
results may not be reproducible if the employed MS, PS, or the other 
devices are different. The MS we employed was an open-cell type, the 
results of which have not been described in many reports other than our 
own7. Closed-cell type MSs have smaller spaces in their interstices 
compared with the open-cell type. Overall, our results seemed excellent  
given the technical difficulties of the procedure. The management of 
occluded MS of the open-cell type deployed in malignant HBS may be 
easier than that of the closed-cell type. 
In conclusion, our long-term data regarding the endoscopic management of 
occluded MSs deployed in malignant HBS are acceptable despite the 
relatively short patency time of PSs deployed after MS occlusion.  
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FIGURE LEGENDS 
FIGURE 1. A 52-year-old male patient with gallbladder carcinoma had MS 
occlusion 445 days after 3-branched multiple MS deployment. After the 
negotiation of the strictures and MS interstices, two guidewires were 
inserted into the MS lumens of the left hepatic duct and the posterior 
branch of the right hepatic duct (A).  The first PS was deployed in the left 
hepatic duct and the remaining MS, deployed in the anterior branch of the 
right lobe, was sought with a guidewire. Then two more PSs were deployed 
in the other lumens (B). 
FIGURE 2.  A 68-year-old male patient received MS cleaning with a 
retrieval balloon (A). After the pull -motion of the retrieval balloon, debris 
appeared through the duodenal papilla (B). 
FIGURE 3.  A 60-year-old woman received four-branched multiple MS 
deployment due to HBS caused by bile duct carcinoma. The stiffness of th e 
papillary end of the MS caused a kink in the bile duct (A: arrow) , and 
sludge was removed by cleaning with a retrieval balloon (B). We inserted 
another MS into the common bile duct with its distal end exposed in the 
duodenum (C).  
FIGURE 4. Survival after MS occlusion 
FIGURE 5. Plastic stent patency 
TABLE 1. Demographic data of patients with unresectable biliary tract carcinoma 
who underwent multiple MS deployment 
 
All 
(n=55) 
Patients with 
MS obstruction (n=30) 
Age, y, mean (range) 69 (52-88) 67 (52-87) 
Gender M/F 32/23 20/10 
Disease 
Cholangiocarcinoma 
Gallbladder carcinoma 
 
42 
13 
 
23 
7 
Bismuth classification 
Ⅱ/Ⅲa/Ⅳ 
 
9/8/38 
 
4/5/21 
Treatment 
Gemcitabine/S-1/BSC 
 
34/8/13 
 
18/5/7 
Mean patency time (days) 229 139 
Median overall survival period (days) 251 460 
Follow-up period (days), mean (range) 232 (30-1741) 427 (75-1741) 
 
MS: metallic stent; BSC: best supportive care 
TABLE 2. Cause of first MS obstruction, endoscopic treatment, and outcome 
Cause n Treatment Outcome 
   
PS 
 
Cleaning 
 
MS 
Technical 
success (%) 
Clinical 
success (%) 
Ingrowth 20 19 0 1 20 (100) 20 (100) 
Sludge 7 0 5 2 7 (100) 7 (100) 
Overgrowth 2 1 0 1 2 (100) 2 (100) 
Hemobilia 1 1 0 0 1 (100) 1 (100) 
 
 
TABLE 3. Times and median interval of PS exchange after MS obstruction 
The number of 
PS exchange 
 
n (%) 
The median interval 
of PS exchange (days) 
0 6 (24)  
1 4 (16) 108 
2 6 (24) 73 
3 5 (20) 56 
more than 4 4 (16) 46 
 









